Ask AI
ProCE Banner Activity

A Year in Review and a Look to the Future: BTKi in CLL and MCL

Conference Coverage
Podcast Episodes

Expert faculty discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, as well as anticipated data from ASH 2023 and the current and potential impact on practice.

Released: November 20, 2023

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Disclosure

Primary Author

Ana Marin-Niebla, MD, PhD

Lymphoma Unit, Vall d’Hebron Institute of Oncology (VHIO)
Head of Section Laboratories of Hematology
Hematology Department
Hospital Universitario Vall d’Hebron
Barcelona, Spain

Ana Marin-Niebla, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene/BeOne, Johnson & Johnson, Takeda.

Stephan Stilgenbauer, MD

Medical Director Comprehensive Cancer Center Ulm (CCCU)
Head Early Clinical Trials Unit (ECTU)
Head Division of CLL Department of Internal Medicine III
Comprehensive Cancer Center Ulm (CCCU)
University of Medical Center Ulm
Ulm, Germany

Stephen Stilgenbauer, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Galapagos, Gilead, GSK, Hoffmann-La Roche, Johnson & Johnson; researcher: AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Galapagos, Gilead, GSK, Hoffmann-La Roche, Johnson & Johnson.